The FMD Vaccine Challenge Project is dedicated to finding a solution-agnostic approach to addressing the problem of FMD in Eastern Africa, and encourages all interested parties to apply. All information relevant to the competition and to potential competitors will be shared on this website and via a mailing list (sign up at the bottom of this page). Please send any inquiries to FMDchallenge@galvmed.org, and the Project Manager will respond in a timely manner.
Resources directly related to the AgResults FMD Vaccine Challenge Project:
OIE Twinning Project between The World Reference Laboratory for FMD (WRL-FMD) at The Pirbright Institute, UK, and The African Union Panafrican Veterinary Vaccine Centre (AU-PANVAC), Ethiopia.
Based on the recommendation of the project’s Technical Committee and specifically for the purposes of the valency test requirement of the project’s Target Product Profile (TPP), we will use the WRLFMD guidance above and apply it to the vaccination regime specified by the manufacturer (using results from either one-dose or two-dose vaccination sera):
As stated in the Competition Rules, with respect to testing for vaccine valency, such data must be generated by an FMD reference laboratory that (a) has the capabilities to test against the full approved Eastern African FMDV Reference Antigen Panel set forth in the Target Product Profile and (b) is neutral, independent, impartial and conflicts-free (including that such laboratory may not have any financial interest in the applicable Competitor or vaccine and may not hold any intellectual property with respect to such vaccine). Pre-approved FMD reference laboratories are listed below, but Competitors should consult with the Project Manager before proceeding with such testing:
Resources indirectly related to the Project:
Foot and Mouth Disease vaccination and post-vaccination monitoring guidelines.
The East African Community Mutual Recognition Procedures (MRP) were developed by national drug registration authorities in the EAC Partner States and endorsed by the EAC. A key objective of the MRP is to allow applicants to save time through simultaneous submissions of quality veterinary medicine dossiers to minimum two EAC countries. Through one submission, other concerned countries may accept the reference country’s assessment of the application. Detailed information is available on the EAC website, including a revised (Oct 2021) version of a Frequently Asked Questions brochure, developed with feedback from industry, National Regulatory Agencies (NRA), and the EAC secretariat on regulatory obstacles around the implementation of MRP.
An annotated version of the Guideline on the Technical Documentation required to be included in a Registration Dossier For an Immunological Veterinary Product has been published by the EAC, specifically to assist assessors with evaluation of vaccines against Foot and Mouth Disease in the context of the EAC MRP.
Note: In recognition of the fact that the Government of Burundi is a signatory of the MRP but does not have the capacity to put in place a national regulatory authority, unless and until the Government of Burundi establishes a national regulatory authority for purposes of administering the MRP, sales of the FMD vaccine in Burundi will be considered to be made under a valid Product Registration if the Competitor receives Product Registration for the FMD vaccine via MRP in at least two (2) other EAC countries (Kenya, Rwanda, Tanzania or Uganda).
Registration in Ethiopia must be done as an individual country registration.
Upon request from vaccine manufacturers, the Project Manager is able to provide contact information for regulators, distributors, logistics companies and potential buyers in the six target countries. These contacts do not necessarily represent a comprehensive list of companies in each of these categories, but rather represent the list of contacts that the Project Manager is aware of at the time of the request, without bias or favouritism. Please send requests to: FMDchallenge@galvmed.org
“Willingness to pay” research studies for livestock vaccines in Eastern Africa: